Tandem Diabetes Care Posts Record Q4 $290M Sales and 58% Margin
Tandem Diabetes Care reported record Q4 worldwide sales of $290 million, up 15% year over year, with U.S. pump shipments hitting a record 27,000 units and gross margin reaching 58%. The company outlined $85–95 million of 2026 headwinds as it shifts to a PayGo pharmacy reimbursement model to boost margins.
1. Record Q4 and Shipment Growth
Tandem Diabetes Care delivered Q4 worldwide sales of $290 million, marking a 15% year-over-year increase. U.S. sales rose 14% to $210 million on a record 27,000 pump shipments, while international revenue grew 17% to $80 million on 11,000 pump shipments.
2. Full-Year Performance and Profitability
Full-year 2025 sales surpassed $1 billion, driven by U.S. revenue of $707 million (up 10%) and international sales of $308 million (up 15%). Gross margin expanded to 54% for the year and 58% in Q4, with adjusted EBITDA at 11% of Q4 sales, a 3% operating margin, and free cash flow generation in H2.
3. 2026 Reimbursement Strategy and Headwinds
Management will accelerate U.S. pharmacy access through a PayGo reimbursement model, expecting $85–95 million of near-term revenue recognition headwinds, including $70–80 million in the U.S. This shift aims to improve patient access, pricing and long-term margins as pharmacy share grows over 2–3 years.
4. Product Pipeline and Market Expansion
The company expanded direct commercial operations in the U.K., Switzerland and Austria, using this playbook for further rollouts in 2026–27. Key product catalysts include expanded Control-IQ+ indications, Mobi integration with FreeStyle Libre 3 Plus, global Dexcom 15-day sensor launch, and a planned H2 2026 FDA submission for Mobi Tubeless.